Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings b

GSK (GSK) trades at a 42% discount to pharma peers, despite resilient earnings projections through t

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics,

GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug

GSK plc (NYSE:GSK) on Friday announced a pivotal update regarding its Phase 3 clinical program for c

GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testin

Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price t

GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for

GSK on ‌Friday said it had decided not to develop ​its experimental drug ​to treat refractory chroni

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal c

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ra

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter result

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter result

GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating

GSK said on Monday its cancer drug Jemperli met the ​primary goal of a mid-stage trial, with ‌a clin

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company mov

British drugmaker ​GSK's experimental ‌drug for treating ​patients ​with advanced or ⁠relapsed ​smal

Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that risvutatug reze

Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement coverin

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China ​unit had secured righ

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its

Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could

FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late

https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult

GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications:As an

During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst

GSK plc (LSE/NYSE:GSK) today announced that momelotinib, a JAK inhibitor with a differentiated mecha

The Nasdaq 100 sank 3.3% Tuesday as AI and optical stocks cratered, while cash rotated into real est

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares su

Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/o

In times of market turbulence, investors turn to dividend-yielding stocks. Benzinga provides real-ti

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

https://www.gov.uk/government/news/mhra-approves-linerixibat-lynavoy-for-the-treatment-of-itch-due-t

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

GSK Q1 earnings beat expectations with $10.22B in sales, driven by strong Shingrix vaccine demand. S

2026 guidance and 2031 sales outlook reaffirmed • Expect 2026 turnover growth of between 3% to 5%; C

GSK (NYSE:GSK) reported quarterly earnings of $1.25 per share which beat the analyst consensus estim

AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the la